# Open Label Study of Long Term Evaluation Against LDL-C Trial

Study · id `cardio:ct-nct01439880` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01439880](<https://clinicaltrials.gov/study/NCT01439880>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01439880

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1324 participants.

## Technical summary

Registry record NCT01439880. Randomized; no masking; primary purpose treatment. Start 2011-10-07 (actual); primary completion 2018-06-20 (actual). Results posted on 2019-07-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1324 participants (enrolled count; ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Started: 2011-10-07 (actual) (ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Primary completion: 2018-06-20 (actual) (ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Completion: 2018-06-20 (actual) (ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Results first posted: 2019-07-10 (ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Canada; Czechia; Denmark; Finland; Germany; Hong Kong SAR China; Hungary; Japan; Netherlands; Norway; Singapore; South Africa; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01439880, source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01439880-2022-09-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open Label Study of Long Term Evaluation Against LDL-C Trial
- Acronym: OSLER
- Condition: Hypercholesterolemia
- Intervention (Biological): Evolocumab
- Intervention (Other): Standard of care
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: e3b1d4c8d04394e3d8a9de6cce316cd07fbc35642d936b98e10c10eba3fbed50
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
